Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Assessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2020 – 2030

Pages: 131 Published: November 18, 2021 Report Code: GDHC224PIDR

The global sales for migraine drugs have been valued at $4.6 billion in 2020 with a CAGR of more than 9%. The US has dominated the migraine market, contributing to more than 80% of the sales in the seven major pharmaceutical markets (7MM) covered – the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. A high market share in US is attributed to the large migraine prevalent population, the costliness of branded drugs, and the number of drugs marketed exclusively in the US compared to other countries in the 7MM. Steady growth has been observed across the European countries over the forecast period.

Overview of the migraine drugs marketOverview of the migraine drugs market

For more insights on this report, download a free report sample

What are the market dynamics and market barriers for the migraine drug market?

Major drivers of the growth within the migraine drugs market include the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs) as a preventive migraine treatment. These drug classes will claim significant patient share across 7MM during the forecast period. The number of 12-month total prevalent cases of migraine is expected to increase during the forecast period, which will lead to an increase in the diagnosed and treated population and drive sales.

Major barriers to the growth of the market include the high use of generic products that are expected to continue throughout the forecast period, the patent expiration of Onzetra Xsail, Trokendi XR, and Reyvow that will lead to cheap generics flooding the market and negatively impacting the branded sales. The ACOTs of anti-CGRP mAbs are significantly higher when compared with the cost of generic triptans and generic oral preventives (antihypertensives, anti-epileptics, and antidepressants).

This may restrict uptake, with payers and physicians’ preference being to prescribe cheaper orally administered alternatives when possible.

12-month total prevalent cases of migraine, 7MM, both sexes, 202012-month total prevalent cases of migraine, 7MM, both sexes, 2020

For more insights, download a free report sample

How has the global COVID-19 pandemic impacted the migraine drugs market?

The neurologic manifestations of COVID-19 suggest a potential entry of the virus into the nervous system via the olfactory groove or the bloodstream. There is strong evidence of COVID-19 mortality being associated with cardiac and pulmonary diseases. Additionally, migraine leads to a higher burden of vascular diseases, which places people with migraine at higher risk of poor COVID-19 outcomes. Acute symptoms of COVID-19 such as fever, sleep disturbance, and dehydration may trigger a migraine episode. Headaches due to COVID-19 were described as pulsating, pressing, or stabbing in quality, and were mostly bilateral, of longer duration, resistant to analgesia, and are more common in males. This makes people with migraine particularly vulnerable to the chronic and indirect effects of the pandemic, including low mood, post-viral fatigue, anxiety, and depression.

What is the disease management and treatment overview for migraine?

Episodic migraine

In cases where patients suffer from a small number (one or two) migraines per month, nonsteroidal anti-inflammatory drugs (NSAIDs) are being prescribed and are taken upon the onset of a migraine. However, in patients with more frequent migraine days, triptans are being prescribed as first-line treatments and can be used in combination with NSAIDs.

In cases where the patient experiences four or more attacks per month, physicians look to prescribe an oral preventive treatment, such as antidepressants, anti-epileptics, and beta-blockers. The specific types of preventive treatment vary among countries in the 7MM.

Chronic migraine

The initial treatment of chronic migraine, classified as 15 or more migraines per month, aims to reduce the frequency, severity, and duration of migraine attacks. Triptans may be prescribed as acute therapy, but due to the number of migraines suffered by those with chronic migraine, this may lead to MOH. Thus, preventive migraine treatments are usually prescribed immediately to these patients. Again, first-line treatment with oral preventives is personalized based on the patient’s need and the physician’s preference. Antidepressants, anti-epileptics, and beta-blockers are the main classes prescribed as first-line oral preventive therapies.

What are the key players in the migraine drugs market?

Companies such as GlaxoSmithKline, Merck, and Pfizer are the three biggest players in the migraine market with products such as Imitrex, Amerge, Maxalt, and Relpax. Players such as Teva, Amgen, Eli Lilly and Lundbeck are also expected to contribute largely to the market as evidenced by the sales of their respective CGRP-targeting mAbs, Ajovy, Aimovig, Emgality, and Vyepti.

Biohaven is anticipated to remain a strong player in the migraine market with an expanding CGRP-targeting portfolio of small molecules. Furthermore, Axsome therapeutics, Impel Neuropharma, Zosano Pharma, and Satsuma pharmaceuticals are expected to be strong contenders in the migraine market.

Migraine drug market, by key players

Migraine drug market, by key players

For more insights, download a free report sample

Market report scope

Market size (Year – 2020) $4.6 billion
Growth rate CAGR of >9% from 2021 to 2025
Base year for estimation 2020
Market segments by country The US, France, Germany, Italy, Spain, the UK and Japan
Forecast period 2021-2025
Key players GlaxoSmithKline, Merck, Pfizer, Teva, Amgen, Eli Lilly and Lundbeck and Biohaven

Scope

This report provides a comprehensive analysis of the Migraine Drug market-

  • Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the migraine therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

The prevalence of migraine is increasing in line with population growth in the 7MM.

Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients’ comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.

The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.

The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.

The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

AbbVie
Amgen
Axsome Therapeutics
Biohaven Pharmaceuticals
Bristol-Myers Squibb
Currax Pharmaceuticals
Eli Lilly
Endo International
Exeltis Healthcare
GlaxoSmithKline
H.Lundbeck
Impel NeuroPharma
Merck
Novartis
Old API Wind-down
Pfizer
Teva Pharmaceuticals
Satsuma Pharmaceuticals
Sosei Heptares
Zosano Pharma Corp

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Migraine: Executive Summary

1.1 Migraine Therapeutics Market will grow to $12.0B

1.2 Key Players Will Maintain Their Competitive Position

1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs

1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

3.2.1 Premonitory Phase

3.2.2 Aura Phase

3.2.3 Headache Phase

3.2.4 Resolution Phase

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 7MM Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine

4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency

4.4.5 12-Month Total Prevalent Cases of Migraine by Type

4.4.6 12-Month Diagnosed Prevalent Cases of Migraine

4.5 Epidemiological Forecast for Migraine (2020-2030)

4.5.1 12-Month Total Prevalent Cases of Migraine

4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine

4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine

4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic

4.5.5 12-Month Total Prevalent Cases of Migraine by Type

4.5.6 12-Month Diagnosed Prevalent Cases of Migraine

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 Episodic Migraine

5.1.2 Chronic Migraine

5.2 Additional KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders

7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication

7.4 Access to Effective and Tolerable Prophylactic Treatments

7.5 Physician Education for Diagnosis

7.6 Raise Awareness of the Disease in the General Population

8 R&D Strategies

8.1 Overview

8.1.1 Gepants for Dual-Acting Acute and Preventive Indications

8.1.2 Preventive Drugs with Long Duration of Action

8.1.3 Improving Efficacy of Marketed Migraine Drugs

8.1.4 Novel MOAs

8.2 Clinical Trials Design

8.2.1 Study Design

8.2.2 Endpoints for Migraine Clinical Trials

8.2.3 Patient Recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Acute Treatment for Migraine

10.2.2 Preventive Treatment for Migraine

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Managing Epidemiologist

13.6.6 Global Director of Therapy Analysis and Epidemiology

13.6.7 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Disease Migraine: Key Metrics in the 7MM

Table 2: Migraine Classification from the ICHD-3

Table 3: Diagnostic Criteria for Migraine with Aura

Table 4: Diagnostic Criteria for Migraine without Aura

Table 5: Risk Factors and Comorbidities for Migraine

Table 6: Treatment Guidelines for Disease Migraine

Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM

Table 8: Migraine Market – Global Drivers and Barriers, 2020–2030

Table 9: Key Events Impacting Sales for Migraine in the US, 2020–2030

Table 10: Migraine Market – Drivers and Barriers in the US, 2020–2030

Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020–2030

Table 12: Migraine Market – Drivers and Barriers in the 5EU, 2020-2030

Table 13: Key Events Impacting Sales for Migraine in Japan, 2020–2030

Table 14: Migraine Market – Drivers and Barriers in Japan, 2020– 2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.

Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.

Figure 5: Pathophysiology of a Migraine

Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020

Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine

Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency

Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type

Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine

Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020

Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020

Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020

Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020

Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

Figure 17: Unmet Needs and Opportunities in Migraine

Figure 18: Overview of the Development Pipeline in Migraine

Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Migraine in the 7MM During the Forecast Period

Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.

Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.

Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030

Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030

Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030

Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030

Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030

Frequently Asked Questions

The migraine drug market was valued at $4.6 billion in 2020.

There are seven major pharmaceutical markets (7MM) covered in this report: The US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan.

GlaxoSmithKline is the leading player in the migraine drug market followed by Merck, Pfizer, Teva, Amgen, Eli Lilly, and Lundbeck, and Biohaven.

$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Central Nervous System
New
Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis…
$3,950 | November 2022
Central Nervous System
New
Dry Eye Syndrome Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Central Nervous System
New
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical…
$3,495 | November 2022